Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
Data will soon show whether Avadel’s FT218 is more convenient than Jazz’s Xyrem, while Axovant will be looking for a dose response with its Parkinson’s gene therapy.
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.
Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?
A collaboration over four gene therapy programmes substantially beefs up Neurocrine’s pipeline, while Voyager Therapeutics gets a much-needed infusion of credibility.
Neurocrine Biosciences is hoping to untick the box on its previous Tourette’s failures, while Redhill hopes that it has the Talicia keys.
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…